On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Oliver Gautschi

ResearcherPublications, citations & collaboration network

Oliver Gautschi is a researcher indexed in ScholarIQ from OpenAlex & ORCID.

How many works does Oliver Gautschi have?

ScholarIQindexed works

Oliver Gautschi has 484 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does Oliver Gautschi have?

ScholarIQcitation count

Oliver Gautschi has 17,463 citations in the OpenAlex counts ScholarIQ stores.

What is the h-index of Oliver Gautschi?

ScholarIQh-index

Oliver Gautschi has an h-index of 62 in OpenAlex.

What is the i10-index of Oliver Gautschi?

ScholarIQi10-index

Oliver Gautschi has an i10-index of 186 in OpenAlex.

What is the ORCID of Oliver Gautschi?

ScholarIQorcid

The ORCID for Oliver Gautschi is on the source record.

What is the OpenAlex record for Oliver Gautschi?

ScholarIQopenalex

The OpenAlex for Oliver Gautschi is on the source record.

What are the most-cited papers on Oliver Gautschi?

ScholarIQmost cited works
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J. Mazieres, Alexander Drilon, Amélie Lusque, Laurent Mhanna, Alexis B. Cortot, Laura Mezquita, Alesha A. Thai, Céline Mascaux, S. Couraud, Rémi Veillon, Michel M. van den Heuvel, Joel W. Neal, Nir Peled, Martin Früh, Terry L. Ng, V. Gounant, Sanjay Popat, Joachim Diebold, Joshua K. Sabari, Viola W. Zhu, Sacha I. Rothschild, Paolo Bironzo, Alex Martínez‐Martí, Alessandra Curioni‐Fontecedro, Rafael Rosell, Mickaël Lattuca-Truc, Marcel Wiesweg, Benjamin Besse, Benjamin Solomon, Fabrice Barlési, Robert D. Schouten, Heather A. Wakelee, D. Ross Camidge, Gérard Zalcman, Silvia Novello, Sai‐Hong Ignatius Ou, Julie Milia, Oliver Gautschi
Annals of Oncology. 20191,375 CitationsOPEN ACCESS
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
Alexander Drilon, Geoffrey R. Oxnard, Daniel Shao-Weng Tan, Herbert H. Loong, Melissa L. Johnson, Justin F. Gainor, Caroline E. McCoach, Oliver Gautschi, Benjamin Besse, Byoung Chul Cho, Nir Peled, Jared Weiss, Yu-Jung Kim, Yuichiro Ohe, Makoto Nishio, Keunchil Park, Jyoti D. Patel, Takashi Seto, Tomohiro Sakamoto, Ezra Y. Rosen, Manisha H. Shah, Fabrice Barlési, Philippe A. Cassier, Lyudmila Bazhenova, Filippo de Braud, Elena Garralda, Vamsidhar Velcheti, Miyako Satouchi, Kadoaki Ohashi, Nathan A. Pennell, Karen L. Reckamp, Grace K. Dy, Jürgen Wolf, Benjamin Solomon, Gerald S. Falchook, Kevin Ebata, Michele Nguyen, Binoj C. Nair, Edward Y. Zhu, Luxi Yang, Xin Huang, Elizabeth Olek, S. Michael Rothenberg, Kōichi Goto, Vivek Subbiah
New England Journal of Medicine. 2020842 CitationsOPEN ACCESS
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
Lori J. Wirth, Eric J. Sherman, Bruce Robinson, Benjamin Solomon, Hyunseok Kang, Jochen H. Lorch, Francis P. Worden, Marcia S. Brose, Jyoti D. Patel, Sophie Leboulleux, Yann Godbert, Fabrice Barlési, John C. Morris, Taofeek K. Owonikoko, Daniel S.W. Tan, Oliver Gautschi, Jared Weiss, Christelle de la Fouchardière, Mark E. Burkard, Janessa Laskin, Matthew H. Taylor, Matthias Kroiß, Jacques Médioni, Jonathan W. Goldman, Todd M. Bauer, Benjamin Levy, Viola W. Zhu, Nehal J. Lakhani, Víctor Moreno, Kevin Ebata, Michele Nguyen, Dana Heirich, Edward Y. Zhu, Xin Huang, Luxi Yang, Jennifer Kherani, S. Michael Rothenberg, Alexander Drilon, Vivek Subbiah, Manisha H. Shah, Maria E. Cabanillas
New England Journal of Medicine. 2020788 CitationsOPEN ACCESS
Lung Cancer That Harbors an <i>HER2</i> Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
Julien Mazières, Solange Peters, Benoît Lepage, Alexis B. Cortot, Fabrice Barlési, Michèle Beau‐Faller, Benjamin Besse, Hélène Blons, Audrey Mansuet-Lupo, T. Urban, Denis Moro‐Sibilot, Éric Dansin, C. Chouaïd, Marie Wislez, Joachim Diebold, Enriqueta Felip, Isabelle Rouquette, Julie Milia, Oliver Gautschi
Journal of Clinical Oncology. 2013659 Citations
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
Alice T. Shaw, Tae Min Kim, Lucio Crinò, Cesare Gridelli, Katsuyuki Kiura, Geoffrey Liu, Silvia Novello, Alessandra Bearz, Oliver Gautschi, Tony Mok, Makoto Nishio, Giorgio V. Scagliotti, David R. Spigel, Stéphanie Deudon, Cheng Zheng, Serafino Pantano, Patrick Urban, Cristian Massacesi, Kalyanee Viraswami-Appanna, Enriqueta Felip
The Lancet Oncology. 2017582 CitationsOPEN ACCESS

Related on ScholarIQ

470M+ articles · free account